AstraZeneca manufactures the brand-name Crestor, and Pfizer makes the brand-name Lipitor. Crestor and Lipitor are mainly used in adults; however, in some instances, they may be used in children. Crestor and Lipitor are used to reduce cholesterol. Crestor or Lipitor should be used, along with a diet low in saturated fat and cholesterol, when diet alone has not adequately worked to lower cholesterol. They also increase HDL cholesterol, the good kind of cholesterol. Other indications are listed in the chart below.
Crestor and Lipitor have not been studied in the treatment of Fredrickson Type I and V dyslipidemias. They looked at the effects of Lipitor, Crestor, Zocor , and Pravachol on lowering LDL low-density lipoprotein cholesterol after six weeks. The study concluded that Crestor lowered LDL cholesterol by 8.
Crestor also increased HDL cholesterol the good kind of cholesterol more than Lipitor did. All statins were similarly tolerated. Coronary atherosclerosis is a narrowing of blood vessels and buildup of calcium and fatty deposits in the arteries, making it harder for blood to get to the heart, and increasing the risk of coronary heart disease. The study also looked at safety and side effects.
Although, it may be worth noting that AstraZeneca, manufacturer of Crestor, funded this study. Also, these drugs were given at the highest doses, which is not as common in a clinical setting for the average patient. Both Crestor and Lipitor induced regression of atherosclerosis to a similar extent. Both drugs were well tolerated and had a low incidence of lab abnormalities. In a clinical setting, both drugs are widely prescribed and well-tolerated. The most effective medication for you can be determined by your healthcare provider, who can consider your medical conditions, history, and medications you take that could interact with Crestor or Lipitor.
Crestor or Lipitor are covered by most insurance and Medicare prescription plans in their generic forms of rosuvastatin or atorvastatin.
Choosing the brand-name product will likely result in a higher copay or may not be covered. Fifty patients were included in the study for each statin dose, and these had to have been on the same dose for at least 2 years between the periods indicated previously.
The prescribed doses in HMC for diabetic patients with dyslipidemia are as follows:. Patients had been checked 3 times to exclude duplications which finally resulted in a total sample of patients. The researcher developed a structured data collection sheet for this study. The designed data collection sheet was tested among 25 patients as a pilot study. Thereafter, any discrepancies found between the data collection sheet and the data available in the Medical Record were resolved.
The first part included the type of statin prescribed for the patient for at least 2 years continuously and dose of statin.
The second part included information about sociodemographic characteristics including age, sex, nationality, height, weight, and BMI. Lifestyle habits like smoking and alcohol intake were included in the second section.
The third section collected information about type of DM, its duration, and presence of hypertension. The fourth section included items about laboratory investigations such as fasting blood glucose, glycated hemoglobin HbA1C , total cholesterol, HDL and LDL cholesterol levels, triglycerides, creatine kinase level, serum creatinine, bilirubin, LFTs, GGT, and serum albumin and adverse events like microalbuminuria and macroalbuminuria.
Data were analyzed using SPSS version Student's t -test was used to ascertain the significance of differences between mean values of two continuous variables and confirmed by nonparametric Mann-Whitney test.
In addition, paired t -test was used to determine the difference between baseline and 2 years after regarding biochemistry parameters, and this is confirmed by the Wilcoxon test which is a nonparametric test that compares two paired groups. Chi-square and Fisher exact tests were performed to test for differences in proportions of categorical variables between two or more groups.
Table 1 presents the sociodemographic characteristics of the study population. Finally, all of the statins appear to have reduced rather than raised HDL-C levels. Figure 3 presents the percentage of patients with the new onset of microalbuminuria after taking statins. Atorvastatin was the safest statin as it resulted in the least number of patients at the end of 2 years of treatment with the new onset of microalbuminuria Number of patients with no microalbuminuria at baseline but developed it after 2 years.
Table 3 presents an overview of the safety profile of each of the statins at their various doses among patients. A slightly adverse effect of statins on renal function was observed due to the new onset of microalbuminuria among some of the patients; nonetheless no case of microalbuminuria progressed to the more dangerous macroalbuminuria.
Safety comparison on hepatic, renal, and muscular functions: adverse events after 2 years of statin use. Indeed, it should be noted that rosuvastatin, which is the latest statin to receive approved labeling by the Food and Drug Administration, has been consistently found to be the most effective at reducing LDL-C levels in the most recent studies comparing its efficacy to other statins [ 25 ].
The lowering of triglycerides is another important goal in reducing CVD risk among diabetic patients [ 5 ]. These findings are similar to the majority of studies in the literature, which have shown a slightly higher reduction in triglycerides in patients taking rosuvastatin in comparison to atorvastatin [ 26 ].
It thus appears that, in relation to this factor triglycerides , that both rosuvastatin and atorvastatin are effective at reducing it. In the current study, all of the statins appear to have reduced rather than raised HDL-C levels.
In this instance, the findings in the current study are contrary to the studies in the literature. A number of factors could be at play which could explain the discrepancy between the current study's results and those in the international literature. It is evident from Table 1 which has the patient characteristics that many of the patients had more than two risk factors for CVD.
For instance, the patients were diabetic, and most of them were over 55 years old and had hypertension. In addition, over two-thirds of the patients were obese and Qatari. In other diabetic research studies conducted in Qatar, it was found that having Qatari ethnicity was correlated with poor lifestyle habits such as sedentary lifestyle and poor eating choices [ 2 , 3 ]. In other words, the subjects had so many other factors which caused their HDL-C levels to be so low that the statins were only able to have a minimal effect.
One of the most common complaints related to statin use is related to the effect of statins on muscular function. Muscle symptoms range from myalgia, which includes muscle pain without creatine kinase CK elevations, to myositis which is muscle symptoms with CK elevations [ 18 ].
In general, elevations of CK of more than ten times the upper limit of normal are regarded as significant elevations justifying the discontinuation of statin treatment [ 28 ]. In other words, all statins, irrespective of dose, were regarded as safe in terms of myositis. Hepatic function is also known to be affected by statin use [ 18 ]. This is mainly measured by asymptomatic elevations of the liver enzymes ALT and AST, otherwise known as transaminitis [ 29 ].
Thus there were no adverse events related to hepatic function reported with the use of any of the statins in the study. This is not surprising, as clinical trials have reported a 0.
Pravastatin is the generic name for Pravachol. Unlike other statin drugs, pravastatin is not extensively metabolized, or processed, by CYP3A4 enzymes in the liver. Instead, pravastatin is broken down in the stomach.
Pravastatin generic tablets are available in strengths of 10 mg, 20 mg, 40 mg, and 80 mg. Pravastatin is usually prescribed to be taken once daily in the evening. It has been shown that pravastatin is more effective when taken in the evening rather than in the morning. Lipitor is a brand-name medication and is available in a generic version called atorvastatin.
Unlike pravastatin, atorvastatin is heavily processed by the CYP3A4 enzyme in the liver. Therefore, atorvastatin may potentially interact with more medications than pravastatin. Lipitor is available in oral tablets with strengths of 10 mg, 20 mg, 40 mg, and 80 mg.
Lipitor can be taken in the morning or evening, and it is usually taken once daily. Pravastatin and atorvastatin can help reduce the risk of heart attacks and strokes in people with coronary heart disease. Both medications can also help reduce the risk of death from heart disease. Risk factors for heart disease include high blood pressure, smoking, and high cholesterol levels. Both pravastatin and atorvastatin are FDA approved to reduce elevated total-cholesterol and LDL levels also known as hyperlipidemia or hypercholesterolemia.
Statin medications can also help treat elevated levels of triglycerides , which are another type of fats or lipids in the body. Someone with elevated levels of triglycerides has hypertriglyceridemia. Pravastatin and Lipitor can also increase HDL levels in the blood. Both pravastatin and atorvastatin are effective medications for treating high blood cholesterol.
The more effective drug depends on your overall condition, the severity of your condition, other drugs you might be taking, and other factors.
One comparative study found that there is no significant difference between pravastatin, simvastatin, and atorvastatin for preventing cardiovascular events.
In other words, these statin drugs were similarly effective for reducing heart attacks and coronary heart disease. A systematic review that pooled over 90 clinical trials compared statin drugs such as fluvastatin, atorvastatin, pravastatin, simvastatin, and rosuvastatin. The review concluded that atorvastatin, fluvastatin, and simvastatin had the highest probability of being the best treatment for preventing cardiovascular events.
Consult a healthcare provider to determine the best statin drug for you. During an AHA press briefing he repeatedly hammered home the message that the absolute risk of an adverse event with Crestor was low -- just cases of rhabdomyolosis or renal complications reported for 5.
Karas said. Nonetheless, he pointed out the increased risk appears early in Crestor treatment and at low doses -- 10 mg. And the AHA signaled its concern about the new study by arranging a telephone press conference to review the study and an accompanying editorial by renowned cholesterol authority Scott Grundy, M.
Elliott Antman, M. But he also noted that the paper had been fast-tracked to publication in just five weeks since "we appreciated that there is significant interest in this topic. In his editorial Dr. Grundy was critical of Dr. Karas's paper and noted that the FDA conducted a "careful and through analysis of the same data" and came up with a different conclusion.
Wolfe, M. Moreover, during the press briefing Dr.
0コメント